Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells

Journal of the National Cancer Institute

Volumn 92, Issue 15, 2000, Pages 1210-1216

  Marks, P A ^a   Richon, V M ^a   Rifkind, R A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 CARBOXYCINNAMIC ACID BISHYDROXAMIC ACID; ANTINEOPLASTIC AGENT; APICIDIN; BUTYRIC ACID; DEPSIPEPTIDE; DEPUDECIN; ENZYME INHIBITOR; HISTONE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; MS 27275; OXAMFLATIN; PYROXAMIDE; SUBERIC BISHYDROXAMIC ACID; TRAPOXIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; APOPTOSIS; CANCER THERAPY; CELL DIFFERENTIATION; CELL TRANSFORMATION; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; NONHUMAN; NUCLEOSOME; PRIORITY JOURNAL; REVIEW;

EID: 0034596309     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.15.1210     Document Type: Review

References (84)

1. Erythroleukemic differentiation
2. Reversibility of differentiation and proliferative capacity in avian myelomonocytic cells transformed by tsE26 leukemia virus
3. The effect of cells transferred into the mouse blastocyst on subsequent development
4. Breast cancer: Induction of differentiation by embryonic tissue
5. Participation of myeloid leukaemic cells injected into embryos in haematopoietic differentiation in adult mice
6. Totipotency and normal differentiation of single teratocarcinoma cells cloned by injection into blastocysts
7. The effects of cells transferred into mouse blastocyst on subsequent development
8. Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: Stimulation of erythroid differentiation by dimethyl sulfoxide
9. A new group of potent inducers of differentiation in murine erythroleukemia cells
10. Inducing differentiation of transformed cells with hybrid polar compounds: A cell cycle-dependent process
11. Different susceptibilities of human melanoma and breast carcinoma cell lines to retinoic acid-induced growth inhibition
12. Modulation of the terminal differentiation of human squamous carcinoma cells in vitro by all-trans-retinoic acid
13. The induction of differentiation in teratocarcinoma stem cells by retinoic acid
14. Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro
15. Effects of retinoids on induction of differentiation of cultured mouse myeloid leukemia cells
16. Novel vitamin D analogs that modulate leukemic cell growth and differentiation with little effect on either intestinal calcium absolution or bone mobilization
17. Differentiating agents in cancer therapy
18. Induction of terminal differentiation in human promyelocytic leukemia cells by tumor-promoting agents
19. Tumors as caricatures of the process of tissue renewal: Prospects for therapy by directing differentiation
20. Histone acetylation and chromatin structure and transcription
21. p300 gene alterations in colorectal and gastric carcinomas
22. Distinct interactions of PML-RARalpha and PLZF-RARalpha with corepressors determine differential responses to RA in APL
23. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia
24. Role of the histone deacetylase complex in acute promyelocytic leukaemia
25. A new antifungal antibiotic, trichostatin
26. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A
27. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase
28. Butyrate as a differentiating agent: Pharmacokinetics, analogues and current status
29. Trichostatin A and trapoxin: Novel chemical probes for the role of histone acetylation in chromatin structure and function
30. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase
31. Phenylbutyrate (PB) for refractory solid tumors: Phase I clinical and pharmacologic evaluation of intravenous and oral PB
32. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors
33. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor
34. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
35. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase
36. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma
37. Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA)
38. Hybrid polar inhibitors of histone deacetylase suppress the growth of the CWR22 human prostate cancer xenograft
39. Chemopreventive efficacy of suberanilohydroxamic acid (SAHA), a cytodifferentiating agent, against tobacco-specific nitrosamine 4-(methylnitros-amino)-1-(3-pyridyl)-1 butanone (NNK)-induced lung tumorigenesis
40. Antitumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate
41. Chromatin structure: A repeating unit of histones and DNA
42. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome
43. Crystal structure of the nucleosome core particle at 2.8 A resolution
44. Covalent modifications of histones: Expression from chromatin templates
45. Histone acetylases and deacetylases in cell proliferation
46. The CBP co-activator is a histone acetyltransferase
47. The transcriptional coactivators p300 and CBP are histone acetyltransferases
48. The TAF(II)250 subunit of TFIID has histone acetyltransferase activity
49. Steroid receptor coactivator-l is a histone acetyltransferase
50. The BRCA2 is a histone acetyltransferase
51. Drosophila CBP represses the transcription factor TCF to antagonize Wingless signalling
52. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p
53. Characterization of a human RPD3 ortholog, HDAC3
54. Three proteins define a class of human histone deacetylases related to yeast Hda1p
55. Identification of a new family of higher eukaryotic histone deacetylases. Coordinate expression of differentiation-dependent chromatin modifiers
56. A new family of human histone deacetylases related to Saccharomyces cerevisiae HDA1p
57. HDAC4 deacetylase associates with and represses the MEF2 transcription factor
58. Isolation of a novel deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression
59. Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor
60. Post synthetic modifications of histone: A mechanism for the control of chromosome structure by the modulation of histones - DNA interactions
61. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer
62. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription
63. Methylation-induced repression - Belts, braces, and chromatin
64. ATP-dependent chromatin-remodeling complexes
65. The 'dark side' of chromatin remodeling: Repressive effects of transcription
66. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain
67. Regulation of activity of the transcription factor GATA-l by acetylation
68. Acetylation of general transcription factors by histone acetyltransferases
69. Rb interacts with histone deacetylase to repress transcription
70. Retinoblastoma protein recruits histone deacetylase to repress transcription
71. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP
72. MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3)
73. Conjunction dysfunction: CBP/p300 in human disease
74. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase
75. Initial clinical evaluation of 'transcription therapy' for cancer: All-trans retinoic acid plus phenylbutyrate
76. The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression
77. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex
78. Apicidin: A novel antiprotozoal agent that inhibits parasite histone deacetylase
79. Potent cytodifferentiating agents related to hexamethylenebisacetamide
80. Structures of a histone deacetylase homologue bound to TSA and SAHA
81. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells
82. The expression of a small fraction of cellular gene is changed in response to histone hyperacetylation
83. Both Sp1 and Sp3 are responsible for p21 wafl promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells
84. SAHA induced histone hyperacetylation of the p21(wafl) gene precedes transcription